Uptake and metabolism of iproplatin in murine L1210 cells
- PMID: 2590997
- DOI: 10.1007/BF00694332
Uptake and metabolism of iproplatin in murine L1210 cells
Abstract
Iproplatin is structurally unique among the platinum (Pt) agents in the clinic because it is a quadrivalent complex. On the basis of the redox parameters for the Pt(IV) and Pt(II) oxidation states in a chloride system, it has been suggested that Pt(IV) complexes will be reduced to Pt(II) complexes in a biological environment. To test this hypothesis, uptake and metabolism studies of [14C]-iproplatin were carried out in L1210 cells. The L1210 cells raised in DBA2/J mice were incubated in vitro with 50 and 100 microM [14C]-iproplatin at 37 degrees C in Hanks' balanced salt solution, and total uptake and radioactivity associated with acid-insoluble fractions were measured for up to 3 h. Under these conditions, the uptake of iproplatin was linear with time and increased with increasing concentrations of iproplatin in the medium. At all times measured, greater than 35% of radioactivity was associated with the acid-insoluble fraction, suggesting binding to macromolecules. The [14C]-labelled compounds in neutralized acid extracts of cells were separated by reverse-phase high-performance liquid chromatography (HPLC). Three labelled compounds were detected; based on chromatographic elution times, they appeared to be iproplatin, cis-dichloro-bis-isopropylamine platinum(II) (CIP), the reduction product of iproplatin, and a third compound more polar than iproplatin and CIP. The finding of free CIP and the macromolecular binding of radioactivity in the cells suggests that iproplatin is reduced intracellularly.
Similar articles
-
DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).Cancer Chemother Pharmacol. 1990;27(3):248-50. doi: 10.1007/BF00685722. Cancer Chemother Pharmacol. 1990. PMID: 2265462
-
Studies on the human metabolism of iproplatin.Cancer Chemother Pharmacol. 1989;25(1):10-4. doi: 10.1007/BF00694331. Cancer Chemother Pharmacol. 1989. PMID: 2590996
-
Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans.Cancer Res. 1988 Jun 15;48(12):3533-6. Cancer Res. 1988. PMID: 3370646
-
An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.Cancer Res. 1991 Feb 1;51(3):969-73. Cancer Res. 1991. PMID: 1988140
-
Platinum antitumour agents: a review of (bio)analysis.Pharm Weekbl Sci. 1992 Jun 19;14(3):61-77. doi: 10.1007/BF01962689. Pharm Weekbl Sci. 1992. PMID: 1630874 Review.
Cited by
-
DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).Cancer Chemother Pharmacol. 1990;27(3):248-50. doi: 10.1007/BF00685722. Cancer Chemother Pharmacol. 1990. PMID: 2265462
-
Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.Br J Cancer. 1996 Aug;74(3):380-6. doi: 10.1038/bjc.1996.369. Br J Cancer. 1996. PMID: 8695352 Free PMC article.
-
Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells.J Exp Pharmacol. 2011 Apr 1;3:43-50. doi: 10.2147/JEP.S13630. eCollection 2011. J Exp Pharmacol. 2011. PMID: 27186109 Free PMC article.
-
Intracellular glutathione and cytotoxicity of platinum complexes.Cancer Chemother Pharmacol. 1995;36(4):271-8. doi: 10.1007/BF00689042. Cancer Chemother Pharmacol. 1995. PMID: 7628045
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous